---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000008"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T14:23:51.441473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Halozyme reports record 2024 revenue of $1.015B, Q4 net income up 60% YoY

## Summary
- Q4 total revenue $298M (+30% YoY); royalty revenue $170M (+40% YoY).
- Q4 GAAP EPS $1.06 (+63% YoY); non-GAAP EPS $1.26 (+54% YoY).
- Full-year 2024 total revenue $1,015M (+22% YoY); net income $444M (+58% YoY).
- Full-year adjusted EBITDA $632M (+48% YoY), exceeding guidance.
- Reiterates 2025 guidance: total revenue $1,150-1,225M, non-GAAP EPS $4.95-5.35.

## SEC filing metadata
- accession: 0001159036-25-000008
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/0001159036-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/halo-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000008
- JSON: https://secwatch.observer/filing/0001159036-25-000008.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.